Genes in Focus
The Biobank is returning results for 3 pharmacogenetic (PGx) genes: CYP2C19, SLCO1B1 & DPYD.
Results that may predict response to medications. Information for healthcare professionals.
Genes in Focus
The Biobank is returning results for 3 pharmacogenetic (PGx) genes: CYP2C19, SLCO1B1 & DPYD.
Prerequisites for Return
In order for results to be available to providers, a Biobank participant must have a blood or saliva sample collected and processed and sign appropriate consent for return.Scroll down to see FAQs
PGx Exceptions
Click here to learn how liver transplant & allogeneic BMT impact PGx results.No. However, CCPM has embedded clinical decision support (CDS) tools into UCHealth’s EHR to notify clinicians of gene-drug interactions at the time of prescribing. As of December 2021, clinical decision support is available for 17 drug-gene pairs affected by variation in CYP2C19 or SLCO1B1.
Please note that not all medications are metabolized by CYP2C19 or transported by SLCO1B1. For medications that are metabolized by CYP2C19, CYP2C19 genotype does not impact outcomes for all medications to the same extent, or does so in an indication-specific manner. For medications that are transported by SLCO1B1, SLCO1B1 genotype does not impact outcomes for all medications to the same extent.
For further information, please visit the drug-gene specific resources and tip sheets below. Additional information can be found on the UCHealth Provider Portal.
For general information about CYP2C19, click here.
For general information about SLCO1B1, click here.
CU Anschutz
Anschutz Health Sciences Building
1890 N Revere Ct
Mailstop F563
Aurora, CO 80045